Medicine
Showing 1,351-1,400 of 2,391 Results
-
Valerie McDonald, MD, PhD
Affiliate, Department Funds
Resident in MedicineBioValerie McDonald received her MD degree from the University of Washington. During medical school, she performed research exploring correlation of a Physical Activity Vital Sign with healthcare system utilization. She is currently a resident physician in Internal Medicine at Stanford Health Care. Her career interests are patient care, research/QI, and innovation in the intersection of cardiovascular and metabolic health.
Prior to medical school, Valerie earned her PhD in environmental engineering at Michigan Technology University, studying sustainable wastewater treatment. She went on to a post-doc fellowship at the Yale Center for Biospheric Studies and Center for Green Chemistry, studying sustainability in stormwater management. She worked as a Professional Engineer for 10 years, consulting on water supply and water quality improvement projects for cities and counties throughout the Western US. -
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). Current studies include: 1) the impact of macronutrient composition on metabolism, DM2 and CVD; 2) comparison of different weight loss diets on metabolism and CVD risk reduction ; 3) role of adipocytes and adipose tissue immune cells in modulating insulin resistance; 4) use of continuous glucose monitoring and multi-omics to define metabolic phenotype and precision diets
-
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Eric Meffre
Professor of Medicine (Immunology and Rheumatology)
BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.
Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative and the Board of Directors at Danaher Corporation.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology. -
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Hector Mendez
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Hector Rodrigo Mendez is a Medical Geneticist from Argentina. Rodrigo completed a residency program in Medical Genetics at Centro Nacional de Genetica Medica – ANLIS (Buenos Aires, Argentina) and a Master’s program in Medical Molecular Biology at Buenos Aires University.
Rodrigo continued his scientific career at a German Genomic Start-up, working as a human geneticist and providing his experience in rare disorders, genomic data (WGS/WES/gene panels) analysis, variant interpretation, and its integration with a deep focus on genotype-phenotype correlation.
Rodrigo’s areas of expertise are rare disorders, NGS technology, Whole Genome Sequencing analysis, and ACMG interpretation guidelines, and his research aims are:
- Collection and analysis of clinical data through deep-learning phenotyping approaches.
- Multi-omic data integration to elucidate complex and rare genetic disorders.
- Drive progress in curing rare genetic diseases, particularly among critically sick infants.
At Stanford University, under the supervision of Dr. Matthew Wheeler, he is conducting his postdoctoral research studies to achieve his scientific goals. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Thomas Charles Merigan M.D.
George E. and Lucy Becker Professor of Medicine, Emeritus
Current Research and Scholarly InterestsI am now emeritus and only participate in university activities through advising my former trainees who have joined the faculty.
-
Matthew Mesias
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioMatthew Mesias, M.D., is a Geriatrician and Clinical Associate Professor of Medicine at Stanford University School of Medicine. He completed his medical degree at Johns Hopkins University School of Medicine and furthered his training internal medicine residency and geriatrics fellowship at the University of Washington. He serves as the Medical Director of the Inpatient Geriatrics Consult Service at Stanford University Hospital. His academic interests include quality improvement in geriatric care, mentorship of medical trainees, and the development of curricula for geriatrics medical education. In 2023, he was awarded the HRSA Geriatric Academic Career Award, which supports his leadership and professional development while creating geriatric educational programs for community-partnered clinics.
-
Everett Meyer
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy), of Pediatrics (Stem Cell Transplantation) and, by courtesy, of Surgery (Abdominal Transplantation)
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
-
Timothy Meyer
Stanford University Professor of Nephrology, Emeritus
Current Research and Scholarly InterestsInadequate removal of uremic solutes contributes to widespread illness in the more than 500,000 Americans maintained on dialysis. But we know remarkably little about these solutes. Dr. Meyer's research efforts are focused on identifying which uremic solutes are toxic, how these solutes are made, and how their production could be decreased or their removal could be increased. We should be able to improve treatment if we knew more about what we are trying to remove.
-
Lekha Mikkilineni
Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)
BioDr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.
Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom’s macroglobunemia.
Dr. Mikkilineni’s research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.
Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.
Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences. -
David Miklos
James and Katherine Lau Professor
Current Research and Scholarly InterestsDr. Miklos is the Chief of BMT & Cell Therapy Program. He leads clinical trials treating patients with lymphoma. His correlative research studies: 1) tumor antigen quantification, 2) single cell functional product characterization, 3) CAR-FACS immune phenotyping of blood and tumor, and identifying mechanisms for CAR-T treatment Failure including antigen loss, CAR-T exhaustion, and CAR suppression.
-
Christina Milcarek
Executive Administrator, Med/Stanford Center for Clinical Research
Current Role at StanfordProviding executive support to:
Dr. Kenneth Mahaffey, Founding Director, Stanford Center for Clinical Research (SCCR) -
Carlos Milla
Professor of Pediatrics (Pulmonary Medicine) and, by courtesy, of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsAt Stanford University I developed and currently direct the CF Translational Research Center. The overarching goal of the center is to provide the groundwork to streamline, accelerate, and promote the translation of basic discoveries into effective therapies and interventions to benefit patients affected by cystic fibrosis. My laboratory group currently has three main lines of investigation: respiratory cell biology in CF; remote biochemical monitoring; and lung physiology in young children.
-
Arnold Milstein
Professor of Medicine (General Medical Discipline)
Current Research and Scholarly InterestsDesign national demonstration of innovations in care delivery that provide more with less. Informed by research on AI-assisted clinical workflow, positive value outlier analysis and triggers of loss aversion bias among patients and clinicians.
Research on creation of a national index of health system productivity gain. -
Vijay Mirmira
Adjunct Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Mirmira believes that excellent communication leads to excellent care, and is dedicated to the health and well-being of his patients and their families. He is fluent in English, Hindi, Tamil and Kannada and has working knowledge of Urdu and Telugu. Apart from enjoying practicing the full scope of family medicine, Dr. Mirmira's special interests include diabetes and thyroid disorders, and pediatric illnesses. He likes to travel and read fiction in his free time.
-
Alicia Mirza
Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
BioDr. Alicia Mirza is quadruple board-certified in Internal Medicine, Pediatrics, Pulmonary Medicine, and Critical Care Medicine. She is now an Assistant Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine (PACCM) at Stanford, where she serves as Associate Director of the Adult Cystic Fibrosis (CF) Program.
She has expertise across a breadth of pulmonary and intensive care domains, with her clinical and research interests centering on CF and bronchiectasis. She is a CF Foundation (CFF) Program for Adult Care Excellence grant awardee. She has worked on quality improvement projects in adult CF care, including initiatives in advanced care planning, pediatric to adult transitions, primary care utilization, and remote monitoring. She is involved in clinical trials as well as registry-based research in both CF and non-CF bronchiectasis.
Nationally, Dr. Mirza was elected to the CHEST Bronchiectasis Network, where she collaborates with experts across the country to expand education in bronchiectasis through podcasts, training modules, and lectures. An active educator, Dr. Mirza teaches Stanford medical students, residents, and fellows. She is engaged both locally and internationally through conference presentations at CHEST, California Thoracic Society, and the North American CF Conference.
She also serves as Co-director of Wellbeing for Stanford PACCM, where she is committed to advancing faculty wellness and fostering a culture of professional fulfillment. In both her clinical and academic work, she emphasizes a holistic approach to supporting patients and colleagues alike, with attention to the whole person and the systems that sustain their health and wellbeing. -
Beverly S. Mitchell, M.D.
George E. Becker Professor of Medicine, Emerita
Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.
-
Masashi Miyauchi
Basic Life Research Scientist, Medicine - Med/Hematology
BioMasashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology. -
Maha Abdalla Mohamed, MD, FACP, FAST
Clinical Associate Professor, Medicine - Nephrology
BioDr. Mohamed is a board-certified, fellowship-trained nephrologist with the Kidney and Pancreas Transplant Program at Stanford Healthcare. She is a clinical associate professor in the Department of Medicine, Division of Nephrology.
Dr. Mohamed specializes in kidney and pancreas transplant outcomes and kidney transplant health equity. Conditions she treats include allografts rejection, recipient BK virus and CMV infection, and post-transplant lymphoproliferative disorder management. Dr. Mohamed is known for her personalized and comprehensive approach to patient care. She takes the time to understand her patients’ unique health needs and creates tailored care plans that fit their lifestyles.
Dr. Mohamed’s research interests include examining new approaches to improving kidney transplant long-term outcome including kidney transplant rejection and infection. She also seeks to develop better screening and monitoring guidance to help reduce post-transplant BK virus and CMV infection.
Dr. Mohamed’s published work can be found in peer-reviewed journals such as Clinical Transplantation, Transplant Infectious Disease and Transplantation. She has presented to her peers at international, national, and regional meetings, including at the American Transplant Congress and the American Society of Nephrology. She has also been invited to speak multiple times at King Faisal Hospital in Rwanda as well as in Kingdom of Saudi Arabia on topics like post-transplant lymphoproliferative disorder, update in kidney transplant rejection, and update in living-donor kidney transplantation.
Dr. Mohamed is a faculty fellow of Stanford Center for Innovation in Global Health, fellow of the American Society of Transplantation, a board of managers member of the AST Transplant Nephrology Fellowship Training Accreditation Program, member of the International Society of Nephrology and the American Society of Nephrology. -
Minal Moharir
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioI was born, raised, and trained in Nashik, India where I completed my formal Medical Education before moving to New York City where I completed my residency in Internal Medicine at New York Downtown Hospital in New York, NY. My interests are in preventative medicne, health and wellness, occupational and environmental safety. In Stanford's Occupational Health Department, I practice clinical occupational medicine while working toward identifying health and safety issues within our enviroment to prevent further injury and illness to our employees.
